Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 12 von 64

Details

Autor(en) / Beteiligte
Titel
Impact of Substrate-Based Ablation of Ventricular Tachycardia on Cardiac Mortality in Patients With Implantable Cardioverter-Defibrillators
Ist Teil von
  • Journal of cardiovascular electrophysiology, 2015-11, Vol.26 (11), p.1230-1238
Ort / Verlag
United States: Blackwell Publishing Ltd
Erscheinungsjahr
2015
Quelle
Alma/SFX Local Collection
Beschreibungen/Notizen
  • Mortality After VT Substrate Ablation Introduction This study sought to determine if the acute procedural outcome of ventricular tachycardia (VT) substrate ablation is associated with a mortality benefit in patients with implantable cardioverter‐defibrillators (ICD). Methods and Results A total of 195 ICD recipients (65 ± 11years) with ischemic or nonischemic dilated cardiomyopathy underwent substrate‐based ablation targeting elimination of local abnormal ventricular activities (LAVA). Acute procedural success, which was defined as elimination of all identified LAVA in addition to the lack of VT inducibility, was achieved in 95 (49%) patients. During a median follow‐up of 23 months, patients with acute procedure success had a significantly lower incidence of ICD shocks compared to those with ablation failure (8% vs. 30%, P < 0.001). In multivariate analysis, acute procedural success was associated with a lower risk of VT recurrence (hazard ratio [HR] 0.30, 95% confidence interval [CI] 0.18–0.49, P < 0.001) and all‐cause mortality (HR 0.32, 95% CI 0.17–0.60, P < 0.001). While the impact of ablation success on mortality was not statistically significant in patients with LVEF > 35% (HR 0.45, 95% CI 0.15–1.34, P = 0.15) and those with NYHA class I/II (HR 0.63, 95% CI 0.29–1.40, P = 0.26), it was marked in patients with LVEF ≤ 35% (HR 0.30, 95% CI 0.14–0.62, P = 0.001) and NYHA class III/IV (HR 0.17, 95% CI 0.05–0.57, P = 0.004). Conclusions LAVA elimination in addition to VT noninducibility as a procedural outcome for substrate‐based ablation is associated with reduced mortality and better VT‐free survival during follow‐up. This prognostic benefit may be most pronounced in patients with severe heart failure as indicated by severely depressed LV function and NYHA class III/IV symptoms.
Sprache
Englisch
Identifikatoren
ISSN: 1045-3873
eISSN: 1540-8167
DOI: 10.1111/jce.12825
Titel-ID: cdi_proquest_miscellaneous_1826623206

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX